Oxford BioTherapeutics, WuXi Biologics team up to create cancer antibodies
Oxford BioTherapeutics has entered a strategic partnership with WuXi Biologics to develop bispecific antibodies for the treatment of several cancer types, expanding on the existing collaboration between the two.
Read More
